Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: Nccn | Mind Blowing Facts

Every Academic Cancer Center Reports a Shortage, and Most Say Community Clinics in Their Region Face Them Too

An NCCN survey found shortages at every responding academic cancer center, and 77% also reported shortage problems at community practices nearby.

Medical Daily · Sep 14

Cancer Patients Needing Ifosfamide Chemotherapy May Receive an Unapproved Imported Version as the U.S. Shortage Persists

An unapproved ifosfamide made for China's market is being imported to ease a U.S. shortage. What cancer patients and caregivers should ask.

Medical Daily · Sep 12

Ifosfamide Is Scarce at 94 Percent of Surveyed Cancer Centers, and Every Responding Center Reports a Drug Shortage

Every cancer center in a new NCCN survey reports at least one drug shortage, led by ifosfamide. What patients in treatment should ask now.

Medical Daily · Sep 11

From analysis to the latest developments in health,
read the most diverse news in one place.

Half of Prostate Focal Therapy Procedures Went to Men Outside the Risk Groups Guidelines Currently Support

A national analysis of 1.18 million men found that 51 percent of prostate focal therapy went to risk groups that the guidelines do not support.

Medical Daily · Aug 17

A Breast Cancer Drug Approved on July 14 Was Added to National Treatment Guidelines Sixteen Days Later

Gedatolisib was placed in the NCCN breast cancer guidelines as a preferred Category 1 option 16 days after FDA approval. What does that rating mean?

Medical Daily · Jul 31

Want to Stay Current on Latest in Cancer Prevention and Treatment? Free Service from NCCN Can Help

PLYMOUTH MEETING, Pa., May 27, 2026 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—the nonprofit alliance of leading cancer centers responsible for essential NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) that providers rely on worldwide—has launched a new, free service. Anyone is now able to sign up for weekly…

AAP · May 27

Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus

Karyopharm Therapeutics (NASDAQ:KPTI) executives said the company expects to provide a fuller presentation of its Phase 3 SENTRY trial data for selinexor in myelofibrosis at the upcoming ASCO conference, while also outlining expected regulatory engagement and other development priorities during a re

MarketBeat · May 26

Read news from The Economist, FT, and more,
with one subscription

Adherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record Quarter

Fennec Pharmaceuticals (NASDAQ:FENC) executives outlined the company’s commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference. Ram Selvaraju, managing dir

MarketBeat · May 23

NCCN Affirms Commitment to Cancer-Related Distress Resources Worldwide During Mental Health Awareness Month

PLYMOUTH MEETING, Pa., May 20, 2026 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—announces that the latest version of the NCCN Distress Thermometer and Problem List, a rapid validated screening tool (0-10 scale) is available in more than 70 languages to identify and address patient…

AAP · May 20

Genetic tests create treatment opportunities and confusion for breast cancer patients

The past decade has witnessed a rapid expansion of genetic tests, including new instruments to inform patients who have been diagnosed with breast cancer about the risk of recurrence and to guide their treatment.

Tribune News Service · Sep 27, 2022

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.